TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28155045

Group type: EXPERIMENTAL
Intervention: Alisertib (selective aurora kinase A inhibitor)
Number of subjects: 22
Study: 28155203

Group type: EXPERIMENTAL
Intervention: Culturally adapted psychoeducation (CaPE) plus Treatment As Usual (TAU)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Culturally adapted psychoeducation (CaPE)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 34
Study: 28157063

Group type: EXPERIMENTAL
Intervention: Cumulative amounts of harmful excipients (ethanol, propylene glycol, benzyl alcohol, parabens, acesulfame p, aspartame, glycerol, sorbitol, polysorbate-80) administered during hospitalization.
Number of subjects: 0
Study: 28157173

Group type: EXPERIMENTAL
Intervention: Nickel patch test in NCWS patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (80 age- and sex-matched subjects with functional gastrointestinal symptoms)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NCWS patients with nickel allergy
Number of subjects: 60
Study: 28157218

Group type: EXPERIMENTAL
Intervention: Pevonedistat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28158311

Group type: EXPERIMENTAL
Intervention: BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, administered as 5 doses totaling 43 mg/kg BW over a 7-week period.
Number of subjects: 4
Study: 28158395

Group type: EXPERIMENTAL
Intervention: Oral challenge with S. Paratyphi A at a dose of 1-5 × 10^3 CFU
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral challenge with S. Paratyphi A at a dose of 0.5-1 × 10^3 CFU
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment started when prespecified diagnostic criteria were met or at day 14 postchallenge
Number of subjects: 20
Study: 28158463

Group type: EXPERIMENTAL
Intervention: Ramucirumab 6 mg/kg Q2W (N = 3)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ramucirumab 8 mg/kg Q2W (N = 6)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ramucirumab 10 mg/kg Q3W (N = 6)
Number of subjects: 15
Study: 28158504

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) including tenofovir disoproxil fumarate
Number of subjects: 463

Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 463
Study: 28158551

Group type: EXPERIMENTAL
Intervention: Concurrent reactivations of herpesviruses (CMV, EBV, HHV-6, HSV-1, HSV-2, VZV)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Concurrent CMV and EBV reactivations
Number of subjects: 329
Study: 28159013

Group type: EXPERIMENTAL
Intervention: High tidal volume
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low tidal volume
Number of subjects: 19
Study: 28159014

Group type: EXPERIMENTAL
Intervention: Robot-assisted esophagectomy (RE)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open esophagectomy (OE)
Number of subjects: 50
Study: 28159192

Group type: EXPERIMENTAL
Intervention: rFIXFc prophylaxis (50-60 IU/kg) once per week, adjusted to ≤100 IU/kg per infusion or up to two times per week as needed
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rFIXFc prophylaxis
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rFIXFc
Number of subjects: 30
Study: 28159311

Group type: EXPERIMENTAL
Intervention: Lactulose/rhamnose enterally on study days 1, 8, and 15
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Exclusive breastmilk feeding
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Antibiotic exposure
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Delayed initiation of feeding ≥4 days
Number of subjects: 43
Study: 28159465

Group type: EXPERIMENTAL
Intervention: Sentinel-lymph-node mapping with complete pelvic lymphadenectomy
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Sentinel-lymph-node mapping
Number of subjects: 385
Study: 28159490

Group type: EXPERIMENTAL
Intervention: ADT plus docetaxel (75mg/m² every 3 weeks for 6 cycles)
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: ADT plus docetaxel
Number of subjects: 790

Group type: COMPARATOR
Intervention: ADT alone
Number of subjects: 790
Study: 28159511

Group type: EXPERIMENTAL
Intervention: Reslizumab IV 3 mg/kg every 4 weeks
Number of subjects: 273

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study: 28159512

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCB) therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sildenafil therapy
Number of subjects: 25
Study: 28159590

Group type: EXPERIMENTAL
Intervention: Polygenic risk scores (PRS) for antidepressant efficacy
Number of subjects: 3756

Group type: EXPERIMENTAL
Intervention: PRS from MDD and schizophrenia
Number of subjects: 3756

Group type: EXPERIMENTAL
Intervention: Stratified by antidepressant (escitalopram or citalopram)
Number of subjects: 3756

Group type: EXPERIMENTAL
Intervention: PRS between pharmacogenetic studies
Number of subjects: 3756

Group type: EXPERIMENTAL
Intervention: Genetic liability to MDD or schizophrenia
Number of subjects: 3756
Study: 28159728

Group type: EXPERIMENTAL
Intervention: 600 mg of flaxseed lignan (secoisolariciresinol diglucoside; SDG) daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 28159731

Group type: EXPERIMENTAL
Intervention: SNAP II (single-channel EEG device)
Number of subjects: 40

Group type: COMPARATOR
Intervention: BIS VISTA (dual-channel EEG device)
Number of subjects: 40
Study: 28159823

Group type: EXPERIMENTAL
Intervention: Higher levels of serum acetyl-carnitines (quartile 4 vs quartile 1)
Number of subjects: 4164

Group type: EXPERIMENTAL
Intervention: Higher levels of serum octanoyl-carnitines (quartile 4 vs quartile 1)
Number of subjects: 4164

Group type: EXPERIMENTAL
Intervention: Higher levels of serum palmitoyl-carnitines (quartile 4 vs quartile 1)
Number of subjects: 4164

Group type: EXPERIMENTAL
Intervention: Elevated serum even-chained acylcarnitines
Number of subjects: 4164
Study: 28159938

Group type: EXPERIMENTAL
Intervention: Sulfatinib formulation 2 (50 and 200 mg capsules)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Sulfatinib (300 mg recommended phase II dose)
Number of subjects: 77
Study: 28160194

Group type: EXPERIMENTAL
Intervention: Constant Troland stimulus
Number of subjects: 18

Group type: COMPARATOR
Intervention: Constant luminance stimulus
Number of subjects: 18
Study: 28160351

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Lithium monotherapy
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Average lifetime definition of rapid cycling
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: DSM-IV definition of rapid cycling
Number of subjects: 129
Study: 28160457

Group type: EXPERIMENTAL
Intervention: Maternal BMI (obese vs. normal weight)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Maternal BMI (overweight and obese vs. normal weight)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Maternal BMI and sex of infant
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Month 1 leptin levels
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Maternal BMI, infant sex, and stage of lactation
Number of subjects: 37
Study: 28160528

Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 2783

Group type: COMPARATOR
Intervention: Open Repair
Number of subjects: 2783
Study: 28161120

Group type: EXPERIMENTAL
Intervention: Venetoclax (ramp-up treatment 20-200 mg) with posaconazole (20 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Venetoclax (reduced dose)
Number of subjects: 12
Study: 28161570

Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine (Shanchol)
Number of subjects: 900

Group type: COMPARATOR
Intervention: No exposure to oral cholera vaccine
Number of subjects: 900
Study: 28162825

Group type: EXPERIMENTAL
Intervention: Quadrivalent live attenuated influenza vaccine (Q/LAIV)
Number of subjects: 62040

Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 62040

Group type: COMPARATOR
Intervention: Inactivated influenza vaccine (IIV) recipients
Number of subjects: 62040
Study: 28163319

Group type: EXPERIMENTAL
Intervention: Homemade complementary food
Number of subjects: 132

Group type: COMPARATOR
Intervention: Commercial complementary food
Number of subjects: 132

Group type: COMPARATOR
Intervention: Both homemade and commercial complementary food
Number of subjects: 132
Study: 28163748

Group type: EXPERIMENTAL
Intervention: Calorie restriction diet and optimal physical activity
Number of subjects: 272

Group type: COMPARATOR
Intervention: Conventional drug treatment with weight loss
Number of subjects: 272
Study: 28163786

Group type: EXPERIMENTAL
Intervention: Revised version of the WHO checklist
Number of subjects: 0
Study: 28163788

Group type: EXPERIMENTAL
Intervention: Quitting smoking
Number of subjects: 1355

Group type: EXPERIMENTAL
Intervention: Engaging in evidence-based cessation assistance
Number of subjects: 1355

Group type: EXPERIMENTAL
Intervention: Adopting strictly enforced smoke-free home policies
Number of subjects: 1355

Group type: EXPERIMENTAL
Intervention: Adopting strictly enforced smoke-free car policies
Number of subjects: 1355

Group type: EXPERIMENTAL
Intervention: Believing that being a smoker got in the way of being a parent
Number of subjects: 1355

Group type: EXPERIMENTAL
Intervention: Believing that thirdhand smoke is harmful to children
Number of subjects: 1355
Study: 28164014

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary interventions (PCI) performed in 175 Russian PCI centers; 531 PCI per 1,000,000 population; 101,451 stents placed (1.37 stents per PCI; 48,057 drug-eluting stents).
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: National policy efforts leading to a documented 27% 10-year decline in CV mortality.
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Dyslipidemia prevalence in trial population (86.7%).
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Obesity prevalence in trial population (16.7%); BMI in trial was 28.4.
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Hypertension prevalence in trial population (86.1%).
Number of subjects: 175
Study: 28164367

Group type: EXPERIMENTAL
Intervention: Severe hyperglycaemia (> 11.1 mmol/l) in people without diabetes
Number of subjects: 7132

Group type: COMPARATOR
Intervention: People with diabetes
Number of subjects: 7132

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 7132
Study: 28165653

Group type: EXPERIMENTAL
Intervention: Targeted biopsy (TB)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Systematic biopsy (SB)
Number of subjects: 161
Study: 28166744

Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 19
Study: 28166794

Group type: EXPERIMENTAL
Intervention: Malaria treatment or any other medication within 14 days
Number of subjects: 2421

Group type: EXPERIMENTAL
Intervention: Insecticide spray within 7 days
Number of subjects: 2421

Group type: EXPERIMENTAL
Intervention: Use of mosquito nets
Number of subjects: 2421

Group type: EXPERIMENTAL
Intervention: Age, rural residence, natural floor, grass/palm roof, unavailability of electricity
Number of subjects: 2421

Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum infection prevalence
Number of subjects: 2421
Study: 28166839

Group type: EXPERIMENTAL
Intervention: Pre-flight evaluation with spirometry and arterial oxygen tension (PaO2) measurements.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Exercise testing as a predictive measure.
Number of subjects: 30
Study: 28167156

Group type: EXPERIMENTAL
Intervention: Eluxadoline 75 mg
Number of subjects: 2814

Group type: EXPERIMENTAL
Intervention: Eluxadoline 100 mg
Number of subjects: 2814

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2814
Study: 28167411

Group type: EXPERIMENTAL
Intervention: Right-hemisphere stroke survivors
Number of subjects: 265

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 265
Study: 28168735

Group type: EXPERIMENTAL
Intervention: Imiquimod (IMQ) pretreatment with NB-UVB therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: NB-UVB therapy alone
Number of subjects: 0
Study: 28168845

Group type: EXPERIMENTAL
Intervention: Drug eluting stents (DES)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Avoiding DAPT drawbacks
Number of subjects: 311
Study: 28169043

Group type: EXPERIMENTAL
Intervention: Preoperative adaptive radiotherapy (ART)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conformal and conventional plans
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 22
Study: 28169974

Group type: EXPERIMENTAL
Intervention: Biological parenteral treatment
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Nonbiological oral treatment
Number of subjects: 79

Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 79
Study: 28171703

Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 865

Group type: COMPARATOR
Intervention: Cesarean delivery
Number of subjects: 865
Study: 28173776

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28173784

Group type: EXPERIMENTAL
Intervention: Comprehensive approach integrating clinical and functional status-based pathology and adapted rehabilitation prescription
Number of subjects: 0
Study: 28173814

Group type: EXPERIMENTAL
Intervention: Vitrification (donor oocytes)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Slow-freezing (donor oocytes)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Vitrification (autologous oocytes)
Number of subjects: 204
Study: 28173852

Group type: EXPERIMENTAL
Intervention: Molecular stool testing (Cologuard® and FIT)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Colonoscopy surveillance
Number of subjects: 4000
Study: 28174148

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam for conscious sedation
Number of subjects: 148

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 148
Study: 28174174

Group type: EXPERIMENTAL
Intervention: Higher observed particle concentration (highest residual quartile)
Number of subjects: 27533

Group type: EXPERIMENTAL
Intervention: Lower observed particle concentration (lowest residual quartile)
Number of subjects: 27533

Group type: COMPARATOR
Intervention: Agreement between markers (middle quartiles)
Number of subjects: 27533
Study: 28174191

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (1.3 MHz, mechanical index 1.3) for 10 minutes after intravenous injection of microbubble contrast agents (2×10)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (1.3 MHz, mechanical index 1.3)
Number of subjects: 2
Study: 28174292

Group type: EXPERIMENTAL
Intervention: Intranasal insulin spray
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 21
Study: 28174487

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) using oxaliplatin plus capecitabine (CapOX)
Number of subjects: 47
Study: 28174664

Group type: EXPERIMENTAL
Intervention: InterWalk Fitness Test
Number of subjects: 0
Study: 28176442

Group type: EXPERIMENTAL
Intervention: Remote Monitoring (RM)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Control (no Remote Monitoring)
Number of subjects: 574
Study: 28177169

Group type: EXPERIMENTAL
Intervention: EEG-based classification algorithm for predicting likelihood of being CT+
Number of subjects: 720
Study: 28177438

Group type: EXPERIMENTAL
Intervention: TG4023 (MVA-FCU1) at doses of 107, 108, or 4 × 108 p.f.u. via intratumoral injection
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5-FC (flucytosine) at a dose of 200 mg/kg/day for 14 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: TG4023/5-FC combination
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Overall treatment with TG4023 and 5-FC
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: TG4023 (MVA-FCU1)
Number of subjects: 16
Study: 28177448

Group type: EXPERIMENTAL
Intervention: Educational intervention in healthy habits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28178062

Group type: EXPERIMENTAL
Intervention: Active recruitment (face-to-face discussions at obstetric appointments)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indirect recruitment (flyers and general emails)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prenatal care provider support
Number of subjects: 0
Study: 28178345

Group type: EXPERIMENTAL
Intervention: Idelalisib + ONO/GS-4059
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Idelalisib + GSK2334470 or MK-2206
Number of subjects: 0
Study: 28178436

Group type: EXPERIMENTAL
Intervention: Multiple nerve blocks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no nerve blocks)
Number of subjects: 90
Study: 28178640

Group type: EXPERIMENTAL
Intervention: Alisertib (30, 40, and 50 mg orally b.i.d., days 1-7 every 21 days) in combination with abiraterone and prednisone (AP)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Alisertib
Number of subjects: 9
Study: 28178885

Group type: EXPERIMENTAL
Intervention: Automatic reference region extraction methodology
Number of subjects: 0
Study: 28178929

Group type: EXPERIMENTAL
Intervention: Latent variable mixture model
Number of subjects: 653

Group type: COMPARATOR
Intervention: Linear model
Number of subjects: 653
Study: 28179030

Group type: EXPERIMENTAL
Intervention: Sebelipase alfa (0.35 mg/kg with intrapatient dose escalation up to 5 mg/kg, once weekly)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Historical control group (n=21)
Number of subjects: 9
Study: 28179222

Group type: EXPERIMENTAL
Intervention: Maternal macronutrient intake during pregnancy
Number of subjects: 0
Study: 28179273

Group type: EXPERIMENTAL
Intervention: Radiation-free conditioning regimen with a T-cell-depleted graft including busulfan, cyclophosphamide, fludarabine, and rabbit anti-thymocyte globulin.
Number of subjects: 45
Study: 28179405

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid procalcitonin (CSF PCT)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Serum procalcitonin (serum PCT)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Conventional biomarkers
Number of subjects: 143
Study: 28179416

Group type: EXPERIMENTAL
Intervention: Childcare during infancy
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Multiple caregivers
Number of subjects: 666
Study: 28179439

Group type: EXPERIMENTAL
Intervention: Inhaled ATP
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Inhaled AMP
Number of subjects: 40
Study: 28179492

Group type: EXPERIMENTAL
Intervention: Indicator Amino Acid-Derived Estimate of Dietary Protein Requirement
Number of subjects: 0
Study: 28179648

Group type: EXPERIMENTAL
Intervention: Dietary intervention (DI) - very-low-calorie diet (VLCD, 500 kcal/day) for 5 weeks
Number of subjects: 15
Study: 28181118

Group type: EXPERIMENTAL
Intervention: Flutemetamol F 18 Injection (185 MBq)
Number of subjects: 70
Study: 28181260

Group type: EXPERIMENTAL
Intervention: Bococizumab (RN316/PF-04950615)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bococizumab (RN316/PF-04950615) with concomitant statins
Number of subjects: 0
Study: 28181668

Group type: EXPERIMENTAL
Intervention: NSI-189
Number of subjects: 0
Study: 28181933

Group type: EXPERIMENTAL
Intervention: Severe intraoperative hyperglycemia (SIH, blood glucose ≥180 mg/dL)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 224
Study: 28182762

Group type: EXPERIMENTAL
Intervention: High 2'FL concentration (1880-2460 mg/L)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low 2'FL concentration (12-42 mg/L)
Number of subjects: 50
Study: 28183321

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pertuzumab, trastuzumab, and docetaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trastuzumab plus docetaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pertuzumab, trastuzumab, and docetaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-trastuzumab-treated group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trastuzumab-containing groups
Number of subjects: 0
Study: 28183354

Group type: EXPERIMENTAL
Intervention: Medicaid expansion (ACA)
Number of subjects: 275000

Group type: EXPERIMENTAL
Intervention: States that expanded Medicaid
Number of subjects: 275000

Group type: COMPARATOR
Intervention: States that did not expand Medicaid
Number of subjects: 275000
Study: 28183713

Group type: EXPERIMENTAL
Intervention: Vaccination targeting native receptors
Number of subjects: 0
Study: 28185086

Group type: EXPERIMENTAL
Intervention: Web-based system (self-screening, patient education, self-referral)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Web-based system
Number of subjects: 20
Study: 28185285

Group type: EXPERIMENTAL
Intervention: Participation in health-related research studies
Number of subjects: 18
Study: 28185288

Group type: EXPERIMENTAL
Intervention: Metformin (2,000 mg/day for 9 or more days prior to surgery)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 50
Study: 28185875

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with a median dose of 24 Gy in 3 fractions
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with androgen deprivation (AD) in 34 patients
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 94
Study: 28186982

Group type: EXPERIMENTAL
Intervention: Biotinylated Trastuzumab (bTrast)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biotinylated Pertuzumab (bPert)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AvidinOX anchorage with biotinylated antibodies
Number of subjects: 0
Study: 28187404

Group type: EXPERIMENTAL
Intervention: Potentized estrogen (12cH, 18cH and 24cH) administered twice daily per oral route for 24 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Potentized estrogen (12cH, 18cH and 24cH)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 28187733

Group type: EXPERIMENTAL
Intervention: Newly developed HRQoL tool
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Exhaled breath temperature (EBT)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Lung function tests
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: 6-min walk test (6MWT)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Genomics, transcriptomics, proteomics
Number of subjects: 500